Hydration and Electrolytes on GLP-1 Medications: What You Actually Need

What the labels say about dehydration

The Wegovy prescribing information lists acute kidney injury due to volume depletion among its warnings and says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1]. Acute kidney injury from dehydration is a warning repeated across current GLP-1 labels [1][2].

The Foundayo (orforglipron) label is the most concrete. It states that acute kidney injury, in some cases requiring hemodialysis, has been reported in patients treated with GLP-1 receptor agonists or with Foundayo, and that the majority of those events occurred in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea. It says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dosage initiation and escalation [2].

In the two pooled Foundayo weight-management trials, acute kidney injury was reported in 0.2% of orforglipron-treated patients versus 0.05% on placebo, and hypotension in 2% versus 0.5%. Among Foundayo-treated patients, hypotension was reported in 4% of those also taking antihypertensive therapy versus 1% of those not on such therapy [2].

How common the fluid-losing side effects are

In 2,116 adults treated with Wegovy 2.4 mg in the weight-management trials, nausea occurred in 44%, diarrhea in 30%, vomiting in 24% and constipation in 24%, against 16%, 16%, 6% and 11% on placebo [1]. For Zepbound 15 mg, pooled rates were nausea 28%, vomiting 13%, diarrhea 23% and constipation 11%, against 8%, 2%, 8% and 5% on placebo [5]. For Foundayo 17.2 mg, nausea was 35%, vomiting 24%, diarrhea 25% and constipation 24%, against 10%, 4%, 11% and 9% [2].

Those rates cannot be lined up to rank the drugs against each other. The labels state that adverse reaction rates from different trials are not directly comparable [1][2]. In the Foundayo trials, nausea, vomiting and diarrhea were more frequent during dose escalation and decreased over time [2]. Severe gastrointestinal reactions were reported in about 3% of orforglipron-treated patients versus 1% on placebo [2].

Do you need electrolyte supplements on a GLP-1 drug?

The labels set no electrolyte target [1][2]. The hydration evidence that does exist is mostly about exercise and heat rather than about GLP-1 drugs.

The American College of Sports Medicine position stand puts the goal of drinking during exercise at preventing fluid loss beyond about 2% of body weight and excessive shifts in electrolyte balance. It notes that sweat rates and sweat electrolyte content vary widely between individuals, so it recommends customized fluid replacement, and that beverages containing electrolytes and carbohydrate can provide benefits over water alone under certain circumstances [4]. A separate review found strength and power largely unaffected by dehydration of up to about 2% to 4% of body mass, while endurance performance can fall at those levels, especially in warm environments. That review also notes that drinking enough to match large sweat losses can itself cause gastrointestinal discomfort [6].

The one water instruction in the labeling: oral tablets

Some tablet forms carry a specific administration rule. The Wegovy tablet label says to take it once daily on an empty stomach in the morning with water (up to 4 ounces), not other liquids, and to wait at least 30 minutes before eating food, drinking beverages or taking other oral medications [1]. Ozempic tablets carry the same 4 ounce water amount and 30 minute wait before food or other oral drugs [3]. Foundayo is different: it is taken once daily with or without food [2].